iBio (NYSEAMERICAN:IBIO) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of iBio (NYSEAMERICAN:IBIOGet Free Report) in a research report issued on Wednesday. The brokerage set a “sell” rating on the stock.

iBio Stock Up 5.0 %

Shares of iBio stock opened at $1.15 on Wednesday. iBio has a 12 month low of $1.02 and a 12 month high of $49.80. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.04.

iBio (NYSEAMERICAN:IBIOGet Free Report) last issued its quarterly earnings results on Friday, February 9th. The company reported ($2.42) EPS for the quarter.

iBio Company Profile

(Get Free Report)

iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.

Read More

Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.